All In Biotech

Drug Trial Radar · NCT07628049

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,456 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,456

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Apr 5, 2029

Study completion Apr 5, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.

Conditions

  • Respiratory Syncytial Virus Infections+Metapneumovirus

Interventions

  • RSV/hMPV_V low dose vaccineBiological

    RSV/hMPV\_V low dose vaccine administered intramuscularly.

  • RSV/hMPV_V medium dose vaccineBiological

    RSV/hMPV\_V medium dose vaccine administered intramuscularly.

  • RSV/hMPV_V high dose vaccineBiological

    RSV/hMPV\_V high dose vaccine administered intramuscularly.

  • RSV/hMPV_W low dose vaccineBiological

    RSV/hMPV\_W low dose vaccine administered intramuscularly.

  • RSV/hMPV_W medium dose vaccineBiological

    RSV/hMPV\_W medium dose vaccine administered intramuscularly.

  • RSV/hMPV_W high dose vaccineBiological

    RSV/hMPV\_W high dose vaccine administered intramuscularly.

  • RSV/hMPV_X low dose vaccineBiological

    RSV/hMPV\_X low dose vaccine administered intramuscularly.

  • RSV/hMPV_X medium dose vaccineBiological

    RSV/hMPV\_X medium dose vaccine administered intramuscularly.

  • RSV/hMPV_X high dose vaccineBiological

    RSV/hMPV\_X high dose vaccine administered intramuscularly.

  • hMPV_Y low dose vaccineBiological

    hMPV\_Y low dose vaccine administered intramuscularly.

  • hMPV_Y medium dose vaccineBiological

    hMPV\_Y medium dose vaccine administered intramuscularly.

  • hMPV_Y high dose vaccineBiological

    hMPV\_Y high dose vaccine administered intramuscularly.

  • hMPV_Z low dose vaccineBiological

    hMPV\_Z low dose vaccine administered intramuscularly.

  • hMPV_Z medium dose vaccineBiological

    hMPV\_Z medium dose vaccine administered intramuscularly.

  • hMPV_Z high dose vaccineBiological

    hMPV\_Z high dose vaccine administered intramuscularly.

  • Control vaccineBiological

    Control vaccine administered intramuscularly.

  • PlaceboCombination product

    Placebo administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Solicited Administration Site EventsTime frame: Day 1 to Day 7
  2. Number of Participants Reporting Solicited Systemic EventsTime frame: Day 1 to Day 7
  3. Number of Participants Reporting Unsolicited Adverse Events (AEs)Time frame: Day 1 to Day 30
  4. Number of Participants Reporting Medically Attended Adverse Events (MAAEs)Time frame: Day 1 to Month 12
  5. Number of Participants Reporting Potential immune-mediated disorders (pIMDs)Time frame: Day 1 to Month 12
  6. Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: Day 1 to study end [Month 24 for OA groups (only the selected formulation group & its comparators) and Month 12 for all other YA groups & OA groups]
  7. Number of Participants Reporting Hematological and Biochemical Laboratory AbnormalitiesTime frame: At Day 1 (pre-vaccination) in Phase 1 groups
  8. Number of Participants Reporting Hematological and Biochemical Laboratory AbnormalitiesTime frame: At Day 8 (post-vaccination) in Phase 1 groups

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Stockbridge, Georgia · Recruiting

  • GSK Investigational Site

    Lenexa, Kansas · Recruiting

  • GSK Investigational Site

    Seattle, Washington · Recruiting

  • GSK Investigational Site

    Botany, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Camberwell, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.